利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.039 秒)

    Humanized antibodies
    13.
    发明申请
    Humanized antibodies 失效
    人源化抗体

    公开(公告)号：US20050090648A1

    公开(公告)日：2005-04-28

    申请号：US10476265

    申请日：2002-04-26

    申请人： Naoya Tsurushita ,  Maximiliano Vasquez

    发明人： Naoya Tsurushita ,  Maximiliano Vasquez

    IPC分类号： C07K16/18 ,  C12P21/08 ,  C07K16/40 ,  A61K39/395 ,  C12N5/06 ,  G01N33/53

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/24

    摘要： Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.

    摘要翻译： 公开了保留小鼠3D6的结合特性的小鼠抗体3D6的人源化形式。 还公开了制备人源化抗体的方法，用于制备人源化抗体的中间体，包括核苷酸序列，载体，转化的宿主细胞，以及使用人源化抗体治疗，预防，缓解，逆转或以其他方式改善症状或病理学的方法 或两者都与唐氏综合征或临床前或临床阿尔茨海默病或脑淀粉样血管病相关。

    Anti-OX40 antibodies and methods of treating cancer
    19.
    发明授权
    Anti-OX40 antibodies and methods of treating cancer 有权
    抗OX40抗体及其治疗方法

    公开(公告)号：US09163085B2

    公开(公告)日：2015-10-20

    申请号：US14240535

    申请日：2012-02-09

    申请人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    发明人： Yong-Jun Liu ,  Kui Shin Voo ,  Laura Bover ,  Naoya Tsurushita ,  J. Yun Tso ,  Shankar Kumar

    IPC分类号： C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/75

    摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

    摘要翻译： 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。

    Generation, expression and characterization of the humanized K33N monoclonal antibody
    20.
    发明授权
    Generation, expression and characterization of the humanized K33N monoclonal antibody 有权
    人源化K33N单克隆抗体的产生，表达和表征

    公开(公告)号：US08735552B2

    公开(公告)日：2014-05-27

    申请号：US13201847

    申请日：2010-03-10

    申请人： Shankar Kumar ,  J. Yun Tso ,  Naoya Tsurushita ,  Tatsuhiro Harada

    发明人： Shankar Kumar ,  J. Yun Tso ,  Naoya Tsurushita ,  Tatsuhiro Harada

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2839 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6887

    摘要： The present invention provides humanized antibodies that immunospecifically recognize human 9 integrin. Some of these antibodies inhibit the biological functions of the 9 integrin, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with 9 integrin, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.

    摘要翻译： 本发明提供免疫特异性识别人9整联蛋白的人源化抗体。 这些抗体中的一些抑制9整联蛋白的生物学功能，从而对与9种整合素（包括癌症）相关的各种疾病或疾病表现出治疗效果，例如癌细胞的生长和转移，以及炎性疾病，例如类风湿 关节炎，骨关节炎，肝炎，支气管哮喘，纤维化，糖尿病，动脉硬化，多发性硬化，肉芽肿，炎性肠病（溃疡性结肠炎和克罗恩病），自身免疫性疾病等。